📇 Rhumatologue · PARIS · (75) · Salarié

MME RUTH GUTHMANN-LEVY

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
34 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 PARIS (75)SalariéRPPS 10000382555

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

OPHTALMOLOGIE SAINT LAZARE
92 RUE SAINT LAZARE, 75009 PARIS
Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Chondroitin sulfate: From bioactive molecule to versatile drug delivery system for advancing regenerative medicine

International journal of biological macromolecules · 2025

📚 10 citations🎯 RCR 4.57

Morbidities and comorbidities associated with optic nerve hypoplasia and septo-optic-pituitary dysplasia

Developmental medicine and child neurology · 2025

📚 9 citations🎯 RCR 4.23

Lire l'abstract Crossref ↓

AbstractAimTo quantify optic nerve hypoplasia (ONH) and septo‐optic‐pituitary dysplasia (SOD) morbidities and comorbidities.MethodA retrospective population‐based study with a case–control design was undertaken using administrative health data from Manitoba, Canada. Cases were 124 patients with ONH or SOD (70 males, 54 females; age range 6 months–36 years 8 months [mean 13 years, SD 7 years 2 months]) diagnosed from 1990 to 2019, matched to 620 unrelated population‐based controls (350 males, 270 females; age range 0–36 years 8 months [mean 12 years 5 months, SD 7 years 2 months]) on birth year, sex, and area of residence. Additionally, 76 cases with ONH or SOD (46 males, 30 females; age range 2 years 5 months–36 years 8 months [mean 13 years 11 months, SD 7 years 3 months]) were matched one‐to‐one with sibling controls (40 males, 36 females; age range 7 months–33 years 1 month [mean 11 years 8 months, SD 7 years 3 months]). We used χ2 or Fisher's exact tests to test for differences in prevalence in morbidities and comorbidities between cases and controls; odds ratios (ORs) with 95% confidence intervals (CIs) were estimated. Cox proportional hazards models were used to test for differences in subgroups of cases; hazard ratios and 95% CIs were estimated.ResultsVisual impairment and visual impairment with hypopituitarism were core morbidities associated with ONH and SOD cases respectively compared to unrelated controls (OR = 58.6, 95% CI = 22.5–152.5; OR = 243.4, 95% CI = 32.9–1799.0 respectively). Developmental delay or intellectual disability (OR = 6.9, 95% CI = 3.3–14.4), autism spectrum disorder (OR = 4.0, 95% CI = 2.0–8.3), epilepsy (OR = 14.9, 95% CI = 6.1–36.5), cerebral palsy (OR = 40.9, 95% CI = 14.0–119.6), and mood or anxiety disorders (OR = 1.7, 95% CI = 1.0–2.8) were the comorbidities more common among cases with ONH and SOD. Cases matched to siblings showed similar results except for mood and anxiety disorders.InterpretationVisual impairment and visual impairment with hypopituitarism are the main morbidities in patients with ONH and SOD respectively, while developmental delay or intellectual disability, autism spectrum disorder, epilepsy, cerebral palsy, and mood or anxiety disorders are important comorbidities.

Breast Cancer Upstaging Risk and In Vivo Tumor Growth Rates Associated with Preoperative Delays

Annals of surgical oncology · 2025

📚 4 citations🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background Preoperative delay when treating breast cancer confers poorer outcomes, but growth rates and the upstaging likelihoods per delay interval remain unknown. This study evaluated upstaging risk, nodal spread, and tumor growth rates in vivo while awaiting treatment. Patients and Methods Registry-based data from the national cancer database was reviewed for patients treated between 2010 and 2020 at commission on cancer-accredited facilities, with nonmetastatic, noninflammatory breast cancer, undergoing surgery first. Results Among 1,018,219 patients, 11.5% had primary tumoral upstaging and 14.1% had nodal upstaging. For every 30 d between diagnosis and surgery, the adjusted odds ratios (ORs) for tumor upstaging was 1.11 for ductal carcinoma in situ (DCIS) (95% CI 1.09–1.13, P < 0.0001), 1.13 for cT1 (95% CI 1.11–1.15, P < 0.0001), and 1.18 for cT2 tumors (95% CI 1.15–1.21, P < 0.0001). For invasive tumors, the adjusted 30-d ORs for upstaging in triple negative (TN) primaries were higher (P < 0.0001) at 1.21 (95% CI 1.17–1.25) than hormone receptor-positive (HR+, 1.13; 95% CI 1.12–1.15) and human epidermal growth factor 2-positive (HER2+, 1.09; 95% CI 1.04–1.13). cN0 patients had an adjusted OR for upstaging to node-positive of 1.07 (95% CI 1.06–1.08, P < 0.0001). The number of 30-d intervals for cT1a, cT1b, cT1c, and cT2 tumors to grow 1 mm was 3.95, 2.63, 2.27, and 1.92, respectively, with tumor growth faster in TN tumors (1.29) than HER2+ (4.95) or HR+ (2.35) (P < 0.0001). Conclusions Longer delays risk greater upstaging and nodal spread, explaining the association with higher disease-specific and overall mortality in prior studies. Larger and TN tumors have larger delay-associated upstaging likelihoods and in vivo growth rates, making preoperative delays more impactful in these groups.

Cookies & analyse de trafic

MME RUTH GUTHMANN-LEVY

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (34) — classées par pathologie

Transversal13

Pédiatrie10

Revue générale5

Épidémiologie & registres4

Essai clinique2

Revue / méta-analyse1

Santé mentale / fatigue1

SAPL1

Vascularites des gros vaisseaux1

Vraie vie / RWE1

Partager cette fiche